Company intelligence / Profile preview
Triplet Therapeutics
Cambridge, Massachusetts, United Statestriplettx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Triplet Therapeutics developed TTX-3360, an antisense oligonucleotide targeting MSH3 in the DNA Damage Response pathway. The company showed proof of mechanism in non-human primates and HD mouse models, but some test results revealed concerning toxicity levels. The company shut down in October 2022 before reaching clinical trials.
- Therapeutic areas
- Neurology
- Modalities
- Antisense oligonucleotides (ASOs)small interfering RNA (siRNA)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Triplet Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triplet Therapeutics.